Search results for "Mitomycin"

showing 10 items of 48 documents

Canaloplasty with mitomycin C after previous combined cataract surgery and Schlemm's canal microstent implantation.

2021

We report on a 56-year-old male with primary open-angle glaucoma who underwent mitomycin C augmented canaloplasty enabling filtration in the right eye after cataract surgery combined with a Schlemm’s canal microstent 3 years previously. He showed progressive glaucomatous optic neuropathy and was highly myopic (axial length 32.05 mm, spherical equivalent −18.75 dioptres in the right eye). Augmented canaloplasty was performed uneventfully and 360° catheterisation was achieved followed by the placement of a 10-0 polypropylene suture in Schlemm’s canal. Intraocular pressure (IOP) in the first post-operative day was reduced from 19 to 6 mmHg. At 1-month follow-up IOP was 12 mmHg off glaucoma me…

Male030213 general clinical medicinemedicine.medical_specialtygenetic structuresOpen angle glaucomamedicine.medical_treatmentMitomycinGlaucomaAfter cataractTrabeculectomyCataract03 medical and health sciences0302 clinical medicineOphthalmologyMedicineHumansIntraocular PressureSchlemm's canalbusiness.industryMitomycin CGeneral MedicineCataract surgeryMiddle Agedmedicine.diseaseeye diseasesOphthalmologymedicine.anatomical_structure030221 ophthalmology & optometrysense organsbusinessGlaucoma Open-AngleEuropean journal of ophthalmology
researchProduct

Suture Removal After Trabeculectomy With Fornix-based Conjunctival Flap Leads to Faster Visual Recovery but Not Reduced Astigmatism

2019

PReCIS:: The closing limbal suture after trabeculectomy with a fornix-based conjunctival flap plays no critical role in the development of corneal astigmatism and intraocular pressure (IOP). A standard removal is not recommended. Purpose To investigate the effect of removal of the conjunctival suture after trabeculectomy with fornix-based conjunctival flap on corneal astigmatism, visual acuity, and IOP. Methods Eighty-seven cases of trabeculectomy with mitomycin C with a fornix-based conjunctival flap performed in the eyes of 82 patients (5 patients underwent bilateral trabeculectomy) were enrolled in a prospective randomized study. All surgeries were conducted by the same surgeon (J.W.) in…

MaleAlkylating AgentsIntraocular pressuremedicine.medical_specialtyVisual acuitygenetic structuresMitomycinmedicine.medical_treatmentVisual AcuityGlaucomaTrabeculectomyAstigmatismSurgical FlapsTonometry Ocular03 medical and health sciences0302 clinical medicineSuture (anatomy)OphthalmologymedicineHumansTrabeculectomyProspective StudiesIntraocular PressureAgedmedicine.diagnostic_testbusiness.industrySuture TechniquesFornixAstigmatismRecovery of FunctionMiddle AgedCorneal topographymedicine.diseaseeye diseasesOphthalmology030221 ophthalmology & optometryFemalesense organsmedicine.symptombusinessConjunctivaGlaucoma Open-Angle030217 neurology & neurosurgeryFollow-Up StudiesJournal of Glaucoma
researchProduct

The Size of Subconjunctival Preparation Does Not Influence the Outcome of Trabeculectomy With Mitomycin C

2014

PURPOSE To compare the outcome of fornix-based trabeculectomy with mitomycin C (MMC) using 2 different sizes of subconjunctival preparation (36 mm² compared with 72 mm²). METHODS Prospective, randomized interventional case series. STUDY POPULATION Patients 18 to 85 years of age with open-angle glaucoma and progressive visual field defects under maximum tolerated medical therapy were randomized to undergo initial fornix-based trabeculectomy with MMC (0.2 mg/mL for 5 min) with subconjunctival preparation of 6×6 mm (group A) or 8×9 mm (group B). Main outcome parameters were: intraocular pressure (IOP), best-corrected visual acuity (BCVA), number of 5-fluorouracil (5-FU) injections, and laser s…

MaleAlkylating Agentsmedicine.medical_specialtyIntraocular pressureVisual acuitygenetic structuresMitomycinmedicine.medical_treatmentVisual AcuityGlaucomaTrabeculectomyGroup BTonometry OcularPostoperative ComplicationsOphthalmologymedicineHumansTrabeculectomyProspective StudiesIntraocular PressureAgedAged 80 and overGlaucoma medicationbusiness.industryMitomycin CMiddle Agedmedicine.diseaseCombined Modality Therapyeye diseasesOphthalmologyTreatment OutcomePopulation studyFemaleFluorouracilsense organsmedicine.symptombusinessConjunctivaGlaucoma Open-AngleFollow-Up StudiesJournal of Glaucoma
researchProduct

Trends of incidence and survival in squamous-cell carcinoma of the anal canal in France: a population-based study.

2016

IF 2.415; International audience; Data on anal cancer epidemiology are rare. The aim of this study was to report on trends of incidence and survival for anal cancer in France before the implementation of the human papilloma virus vaccine. This analysis was carried out on 1150 squamous-cell carcinomas of the anal canal diagnosed from 1989 to 2004 in a population of 5.7 million people covered by eight population-based cancer registries. Time trends in incidence were modeled using an age-period-cohort model. Net survival rates were obtained using the recently validated unbiased Pohar-Perme estimator. The incidence of squamous-cell carcinoma of the anal canal increased from 0.2 to 0.5/100 000 p…

MaleEpidemiologyMESH : Aged[ SDV.CAN ] Life Sciences [q-bio]/CancerMESH: Anus NeoplasmsMESH: Research Papers: Gastrointestinal Cancer0302 clinical medicineMESH : ChildMESH: ChildMedicineMESH: IncidenceMESH : Carcinoma Squamous CellChildeducation.field_of_studyMESH: Middle AgedObstetricsMESH : InfantMESH: Carcinoma Squamous CellMESH: Follow-Up StudiesAnal canalAnus NeoplasmsPrognosisResearch PapersMESH: InfantMESH : Incidence3. Good healthSurvival RateOncologyMESH: Young AdultChild Preschool030220 oncology & carcinogenesisCarcinoma Squamous Cell030211 gastroenterology & hepatologymedicine.medical_specialtyMESH : Research Papers: Gastrointestinal CancerMitomycinMESH : Young AdultUnited-StatesMESH: Prognosis03 medical and health sciencesMESH : AdolescentHumansAnal cancerMESH : Middle AgedMESH : Anus NeoplasmseducationAgedGynecologyMESH: AdolescentMESH: HumansMESH : HumansMESH: Child PreschoolPublic Health Environmental and Occupational HealthInfantMESH : Follow-Up StudiesMESH: AdultEpidermoid Carcinomamedicine.diseaseCervical-cancerincidenceRandomized-trialMESH: FemaleCancer ResearchMESH: RegistriesMESH : Child PreschoolRisk FactorsMESH: Risk FactorsMESH : FemaleRegistriesCervical cancerMESH: AgedMESH : PrognosisIncidence (epidemiology)SmokingMESH: Infant NewbornMESH : AdultMiddle AgedMESH : Survival RateMESH : Risk Factorsmedicine.anatomical_structureFemaleFranceAdultHuman-PapillomavirusRiskAdolescentMESH: Survival Rateanal cancerMESH : MalePopulationHuman Papilloma Virus Vaccine[SDV.CAN]Life Sciences [q-bio]/CancerCancer IncidenceMESH : Infant NewbornsurvivalYoung Adultcancer registryMESH : FranceSurvival rateRadiotherapybusiness.industryInfant NewbornCancerMESH: MaleMESH: FrancebusinessMESH : RegistriesFollow-Up Studies
researchProduct

Biodegradable collagen matrix implant versus mitomycin-C in trabeculectomy: five-year follow-up.

2015

Background Clinical studies comparing trabeculectomy augmented with Ologen implant (OLO) versus trabeculectomy plus mitomycin-C (MMC) show contradictory results. To obtain long-term data, we report an extended 5-year follow-up trial evaluating the safety and efficacy of OLO as adjuvant compared to low-dosage MMC in trabeculectomy. Methods Forty glaucoma patients (40 eyes) assigned to trabeculectomy with MMC or Ologen. Primary outcome: target IOP at ≤21, ≤17 and ≤15 mmHg; complete and qualified success endpoint rates. Secondary outcomes: visual acuity (VA), mean deviation (MD), bleb evaluation, according to Moorfields Bleb Grading System (MBGS); spectral domain OCT (SD-OCT) bleb examination;…

MaleIntraocular pressureVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityGlaucomaExfoliation Syndrome0302 clinical medicineAbsorbable ImplantsTrabeculectomyExtended 5-yrs follow-upExtended 5-yrs follow-up; Mitomycin-C; Ologen; Trabeculectomy;GlycosaminoglycansGeneral MedicineMiddle AgedMitomycin-CFemaleCollagenmedicine.symptomGlaucoma Open-AngleTomography Optical CoherenceHumanResearch ArticleAdultmedicine.medical_specialtyAlkylating AgentsMitomycinTrabeculectomyOlogenFollow-Up Studie03 medical and health sciencesAbsorbable ImplantOphthalmologymedicineHumansIntraocular PressureAgedSettore MED/30 - Malattie Apparato Visivobusiness.industryMitomycin CFive year follow upANTIGLAUCOMA MEDICATIONSAlkylating Agentmedicine.diseaseeye diseasesSurgeryOphthalmologyGlycosaminoglycan030221 ophthalmology & optometryImplantsense organsbusiness030217 neurology & neurosurgeryFollow-Up StudiesBMC ophthalmology
researchProduct

Deep sclerectomy versus trabeculectomy with low-dosage mitomycin C: four-year follow-up

2006

<i>Aims:</i> To compare the long-term effects of low-dosage mitomycin C (MMC) in both deep sclerectomy (DSMMC) and trabeculectomy (TPMMC) on intraocular pressure (IOP). <i>Methods:</i> Analysis of extended follow-up of data from a prospective clinical trial. Forty patients were originally randomised to undergo either DSMMC (19 eyes) or TPMMC (21 eyes). Follow-up was performed at postoperative day 1, weeks 1, 2 and 3, as well as months 1, 3, 6, 9, 12, 18, 24, 36 and 48. Two- to three-week data were not included in the statistical analysis. Postoperative complications, number of antiglaucoma medications and IOP were recorded at each visit. Complete (no medications) and…

MaleIntraocular pressuremedicine.medical_specialtygenetic structuresMitomycinmedicine.medical_treatmentEye diseaseGlaucomaKaplan-Meier EstimateExfoliation Syndromelaw.inventionPostoperative ComplicationsRandomized controlled triallawOphthalmologyGlaucoma surgerymedicineHumansTrabeculectomyIntraocular PressureAgedmitomycin CIntraoperative CareDose-Response Relationship Drugbusiness.industrySettore MED/30 - Malattie Apparato VisivoMitomycin Ctrabeculectomydeep sclerectomyclinical trialGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesSensory SystemsSurgeryClinical trialOphthalmologyTreatment OutcomeSclerostomyFemalesense organsbusinessGlaucoma Open-AngleFollow-Up Studies
researchProduct

E-PTFE (Gore-Tex) implant with or without low-dosage mitomycin-C as an adjuvant in penetrating glaucoma surgery: 2 year randomized clinical trial.

2008

Purpose: To test the expanded polytetrafluoroethylene (ePTFE) as a new adjuvant in trabeculectomy. Methods: Consecutive glaucoma surgical inpatients were observed at the Department of Ophthalmology of Palermo University. Sixty patients (60 eyes) were randomly assigned to undergo trabeculectomy (T), trabeculectomy with mitomycin-C (TMMC), with ePTFE (TG) or with mitomycin-C and ePTFE (TGMMC). Postoperative visits were scheduled at 24 hr, 7 days, 1, 3, 6, 12, 18 and 24 months. Complete success and qualified success were assessed at two target intraocular pressure (IOP) levels – £21 and £17 mmHg – by Kaplan–Meier curves. Results: The postoperative IOP reduction was significant (P < 0.01) at th…

MaleIntraocular pressuremedicine.medical_specialtygenetic structuresmedicine.medical_treatmentMitomycinGlaucomaOcular HypotensionTrabeculectomyKaplan-Meier Estimatelaw.inventionRandomized controlled triallawpenetrating glaucoma surgerymedicineGlaucoma surgeryTrabeculectomyHumansPostoperative PeriodSurvival ratePolytetrafluoroethyleneIntraocular PressureE-PTFE (Gore-Tex)implantAgedDose-Response Relationship Drugbusiness.industryMitomycin CGlaucomaGeneral MedicineProstheses and ImplantsMiddle Agedmedicine.diseaserandomized clinical trialSurgerylow-dosage mitomycin-Cpenetrating glaucoma surgery; E-PTFE (Gore-Tex)implant; low-dosage mitomycin-C; randomized clinical trialOphthalmologyChemotherapy AdjuvantAnesthesiaFemaleImplantbusiness
researchProduct

Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial

2011

AIM: To verify the safety and efficacy of Ologen (OLO) implant as adjuvant compared with low-dosage mitomycin-C (MMC) in trabeculectomy. METHODS: This was a prospective randomized clinical trial with a 24-month follow-up. Forty glaucoma patients (40 eyes) were assigned to trabeculectomy with MMC or OLO. Primary outcome includes target IOP at ≤21, ≤17, and ≤15 mm Hg; complete (target IOP without medications), and qualified success (target IOP regardless of medications). Secondary outcomes include bleb evaluation, according to Moorfields Bleb Grading System (MBGS); spectral domain optical coherence tomography (SD-OCT) examination; number of glaucoma medications; and frequency of postoperative…

MaleIntraocular pressuremedicine.medical_specialtymedicine.medical_treatmentMitomycinGlaucomaTrabeculectomyMatrix (biology)law.inventionRandomized controlled triallawAbsorbable ImplantsmedicineTrabeculectomyHumansProspective StudiesIntraocular PressureAgedGlycosaminoglycansIntraoperative CareSettore MED/30 - Malattie Apparato Visivobusiness.industryMitomycin CGlaucomaProstheses and ImplantsMiddle AgedOlogen MMC trabeculectomymedicine.diseaseSurgeryOphthalmologyCross-Linking ReagentsClinical StudyFemaleImplantCollagenbusinessAdjuvantTomography Optical Coherence
researchProduct

The cytotoxicity of mitomycin C and Adriamycin in genetically engineered V79 cell lines and freshly isolated rat hepatocytes

1995

The objective of the present study was to investigate the cytotoxicity of Adriamycin (ADR) and mitomycin C (MMC) in tumor and non-tumor cells with respect to the role of cytochrome P450 (P450). Therefore, genetically engineered V79 Chinese hamster fibroblasts expressing only single enzymes of P450 were used. SD1 and XEM2 cells expressed rat P450IIB1 and P450IA1, respectively, whereas the V79 parental cells contained no detectable P450 levels. The cytotoxicity of ADR and MMC in the V79 cell system was compared with that in freshly isolated hepatocytes from phenobarbital (PB-hepatocytes)- and beta-naphthoflavone (beta NF-hepatocytes)-induced rats. Following 24 h of exposure to ADR equal cytot…

MaleLiver cytologyMitomycinBiologyTransfectionToxicologyDihydroxydihydrobenzopyrenesCricetulusCytochrome P-450 Enzyme Systembeta-NaphthoflavoneSDG 3 - Good Health and Well-beingCricetinaemedicineAnimalsCytotoxic T cellEnzyme InhibitorsRats WistarCytotoxicityCyclophosphamideCells CulturedBenzoflavonesCell DeathL-Lactate DehydrogenaseMitomycin CMaleatesGeneral MedicineTransfectionFibroblastsMetyraponerespiratory systemMolecular biologyIn vitroRatsmedicine.anatomical_structureLiverBiochemistryDoxorubicinCell cultureEnzyme InductionPhenobarbitalHepatocyte/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingChemico-Biological Interactions
researchProduct

A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance

2007

Several different autosomal recessive genetic disorders characterized by ataxia with oculomotor apraxia (AOA) have been identified with the unifying feature of defective DNA damage recognition and/or repair. We describe here the characterization of a novel form of AOA showing increased sensitivity to agents that cause single-strand breaks (SSBs) in DNA but having no gross defect in the repair of these breaks. Evidence for the presence of residual SSBs in DNA was provided by dramatically increased levels of poly (ADP-ribose)polymerase (PARP-1) auto-poly (ADP-ribosyl)ation, the detection of increased levels of reactive oxygen/nitrogen species (ROS/RNS) and oxidative damage to DNA in the patie…

MaleMethylnitronitrosoguanidineProgrammed cell deathAtaxiaDNA RepairApraxiasDNA damageMitomycinBlotting WesternPoly (ADP-Ribose) Polymerase-1Apoptosismedicine.disease_causeAntioxidantschemistry.chemical_compoundRadiation IonizingmedicineHumansDNA Breaks Single-StrandedOculomotor apraxiaMolecular BiologyCells CulturedEtoposideMembrane Potential MitochondrialbiologyCytochrome cHydrogen PeroxideCell BiologyFlow Cytometrymedicine.diseaseAntineoplastic Agents PhytogenicReactive Nitrogen SpeciesMolecular biologyOxidative StresschemistryApoptosisbiology.proteinAtaxiaCamptothecinFemalePoly(ADP-ribose) Polymerasesmedicine.symptomDNAOxidative stressDNA DamageCell Death &amp; Differentiation
researchProduct